RenovoRx, Inc. RNXT
- Market cap
- $75.8M
- P/E
- 0.0×
Follow RNXT
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | 4.67 | 1.50 | 0.53 | 0.77 | 0.70 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | 16.74 | 5.11 | 5.75 | 2.12 | 1.69 |
High Price
|
|||
| — | — | — | — | 8 | 6 | 9 | 8 | 10 | 17 |
Employees
|
|||
| — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | 0 | 1 |
Revenue
|
|||
| — | — | — | — | — | 0.00% | 0.00% | — | 100.00% | 70.88% |
Gross Margin
|
|||
| — | — | — | (4) | (4) | (6) | (10) | (10) | (9) | (11) |
EBT
|
|||
| — | — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (20,497.67%) | (994.48%) |
EBT Margin
|
|||
| — | 0 | — | (4) | (4) | (6) | (10) | (10) | (9) | (11) |
Net Income
|
|||
| — | — | — | — | 0 | 1 | 0 | — | — | 0 |
Depreciation
|
|||
| — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 |
Revenue/Sh
|
|||
| — | — | — | (1.76) | (1.72) | (1.21) | (1.09) | (0.99) | (0.40) | (0.32) |
Earnings/Sh
|
|||
| — | — | — | (1.54) | (1.59) | (1.13) | (0.97) | (1.00) | (0.41) | (0.31) |
Cash Flow/Sh
|
|||
| — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex/Sh
|
|||
| — | — | — | (1.54) | (1.59) | (1.14) | (0.97) | (1.00) | (0.41) | (0.31) |
Free CF/Sh
|
|||
| — | — | — | (5.02) | (6.62) | 2.94 | 0.68 | (0.29) | 0.20 | 0.15 |
Book Value/Sh
|
|||
| — | — | — | 2 | 2 | 5 | 9 | 10 | 22 | 35 |
Shares
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 26.43 |
PS Ratio
|
|||
| — | — | — | — | — | — | — | — | 6.42 | 5.47 |
PB Ratio
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 24.45 |
EV/Sales
|
|||
| — | — | — | — | — | — | — | — | (2.88) | (2.50) |
EV/FCF
|
|||
| — | — | — | (3) | (4) | (6) | (9) | (10) | (9) | (11) |
Op' Cash Flow
|
|||
| — | — | — | — | — | 0 | — | — | 0 | 0 |
Capex
|
|||
| — | — | — | (3) | (4) | (6) | (9) | (10) | (9) | (11) |
FCF
|
|||
| — | — | — | 1 | (2) | 15 | 6 | 0 | 6 | 6 |
Working Cap'
|
|||
| — | — | — | 12 | 3 | — | — | — | — | — |
Total Debt
|
|||
| — | — | — | 10 | 1 | (15) | (6) | (1) | (7) | (7) |
Net Debt
|
|||
| — | — | — | (11) | (15) | 15 | 6 | (3) | 4 | 5 |
Sh' Equity
|
|||
| — | — | — | (338.24%) | (181.55%) | (69.49%) | (83.98%) | (234.38%) | (183.93%) | (137.77%) |
ROA
|
|||
| — | — | — | 0.00% | 0.00% | (2,257.56%) | 0.00% | 0.00% | 0.00% | 0.00% |
ROIC
|
|||
| — | — | — | 30.01% | 29.69% | (1,825.11%) | (91.94%) | (646.98%) | (1,192.69%) | (225.62%) |
ROE
|
|||
RenovoRx, Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| FBIO Fortress Biotech, Inc. | $76.0M | 0.7× | Compare |
| MAIA MAIA Biotechnology, Inc. | $76.0M | 0.0× | Compare |
| GUTS Fractyl Health, Inc. | $76.4M | 0.0× | Compare |
| VRCA Verrica Pharmaceuticals Inc. | $74.9M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| IBIO iBio, Inc. | $77.3M | 0.0× | Compare |
| ACET Adicet Bio, Inc. | $77.4M | 0.0× | Compare |
| OSTX OS Therapies Incorporated | $77.7M | 0.0× | Compare |
| RNTX Rein Therapeutics Inc. | $73.8M | 0.0× | Compare |
RenovoRx, Inc. (RNXT) key facts
- RenovoRx, Inc. (RNXT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- RenovoRx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 million, up 2,511.6% from fiscal 2024.
- RenovoRx, Inc. reported a net loss of $11.2 million, or a loss of $0.32 per share, for fiscal 2025.
- As of September 25, 2026, RNXT traded at $1.66, a market capitalization of $75.8 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 39.7× sales.
- Return on equity was −225.6% and debt-to-equity 0.00.
RenovoRx, Inc. (RNXT) Latest News
2 Sep
RenovoRx will present at H.C. Wainwright to highlight RenovoCath growth and Phase III TIGeR-PaC timeline. Conference presentation on product growth and trial timeline can moderately influence investor sentiment for RenovoRx.
25 Aug
RenovoRx highlights peer-reviewed publication of pharmacokinetic and pharmacodynamic data supporting TAMP platform for targeted drug delivery in locally advanced pancreatic cancer. Peer-reviewed PK/PD data validates core TAMP technology and may boost RenovoRx development prospects in pancreatic cancer.
20 Aug
RenovoRx received a notice of allowance for a new U.S. patent covering RenovoCath, its dual-occlusion catheter for targeted therapeutic drug delivery in cancer treatment. Patent allowance on RenovoCath strengthens RenovoRx intellectual property position and supports future commercialization in targeted cancer therapies.
16 Aug
RenovoRx targets 2027 TIGeR-PaC readout with RenovoCath expansion to 21 centers. Center expansion advances trial infrastructure ahead of distant 2027 readout.
13 Aug
RenovoRx Inc reported record revenue for Q2 2026 and announced strategic expansion plans. Record revenue and strategic expansion plans indicate major positive shifts in financial performance and growth trajectory.
12 Aug
RenovoRx reported record second quarter 2026 results driven by accelerating commercial adoption and 61% sequential quarterly revenue growth. Record quarterly results with 61% revenue growth signal major positive effects on future performance and investor outlook.
RenovoRx, Inc. released its Q2 2026 earnings call summary covering financial results, operational updates, and forward-looking statements for the company. Q2 earnings call delivers financial and strategic updates that moderately influence near-term market sentiment without guaranteed long-term trajectory shifts.
RenovoRx, Inc. (RNXT) released Q2 earnings call highlights covering financial results, operational updates, and forward outlook. Standard quarterly earnings call highlights typically produce moderate short-term market reaction without fundamentally altering company trajectory.
11 Aug
RenovoRx completes full enrollment in its Phase III TIGeR-PaC trial for locally advanced pancreatic cancer. Full Phase III enrollment advances RenovoRx toward potential approval and revenue from pancreatic cancer therapy.
RenovoRx advances its targeted pancreatic cancer therapy with pivotal data expected in 2027. Pivotal data readout for lead therapy in 2027 can materially shift clinical and market trajectory.
6 Aug
RenovoRx announces first commercial clinical use of RenovoCath in sarcoma patient treatment, expanding targeted drug-delivery device to other solid tumors. First commercial deployment of RenovoCath for sarcoma extends device utility across multiple solid tumor types.
11 Jun
RenovoRx highlights peer-reviewed publication supporting intra-arterial gemcitabine delivery via TAMP™ in locally advanced pancreatic cancer. Peer-reviewed validation of TAMP™ technology provides clinical evidence that may support future adoption and investor interest in RenovoRx's core platform.
28 May
RenovoRx receives FDA Orphan Drug Designation for oxaliplatin to treat pancreatic cancer. Orphan Drug Designation grants market exclusivity and development incentives that strengthen RenovoRx valuation and pipeline.
26 May
RenovoRx announces promising pharmacokinetic data using TAMP platform presented at 2026 ASCO Annual Meeting. Positive TAMP data at ASCO boosts clinical credibility and investor outlook for RNXT.
15 May
RenovoRx Inc (RNXT) reported record revenue in Q1 2026 earnings call, driven by strong performance, while announcing strategic expansions including new partnerships and pipeline advancements. Record revenue and strategic expansions represent major growth drivers likely to boost RNXT's market performance and investor sentiment.
RenovoRx, Inc. held its Q1 2026 earnings call, reporting financial results, operational updates, and forward-looking statements on its therapeutic development programs. Quarterly earnings details provide moderate insight into near-term financial health and pipeline status without indicating major strategic shifts.
14 May
RenovoRx, Inc. (RNXT) reported record first quarter 2026 results with revenue surging 136% quarter-over-quarter. 136% QoQ revenue growth represents a major financial milestone that could significantly boost investor sentiment and company trajectory.
RenovoRx, Inc. (RNXT) reported a Q1 loss but exceeded revenue estimates. Q1 loss despite revenue beat affects financial performance and investor sentiment moderately.
7 May
RenovoRx, Inc. (RNXT) is expected to report negative earnings next week, urging investors to review the company's earnings trend ahead of the release. Expected negative earnings will moderately affect RNXT's financial performance and short-term investor sentiment.
23 Apr
RenovoRx, Inc. (RNXT) announced acceptance of a pharmacokinetic and pharmacodynamic data abstract supporting its TAMP™ Therapy Platform for presentation at the 2026 ASCO Annual Meeting. ASCO acceptance signals clinical validation of TAMP™ platform, likely driving significant positive investor sentiment and stock momentum for biotech RNXT.
14 Apr
RenovoRx, Inc. (RNXT) presented clinical data at the 2026 SIR Annual Scientific Meeting supporting targeted chemotherapeutic delivery via its proprietary TAMP™ Therapy Platform. Presentation of supportive clinical data at a major radiology meeting validates RenovoRx's TAMP platform and signals progress toward commercialization, likely enhancing investor sentiment and stock performance.
8 Apr
RenovoRx, Inc. (RNXT) secured its first Notice of Allowance for a Japanese patent covering the RenovoCath® device, enabling targeted local drug delivery via the vasa vasorum. Japanese patent allowance for RenovoCath® enhances RenovoRx's international IP portfolio and supports expansion into Asian markets.
30 Mar
RenovoRx Inc (RNXT) reported strong revenue growth and key strategic advancements in its Q4 2025 earnings call highlights. Strong Q4 2025 revenue growth and strategic initiatives represent major positive shifts poised to significantly enhance RNXT's financial trajectory and investor sentiment.
RenovoRx, Inc. (RNXT) reported full-year 2025 financial results and provided a business update. Full-year financial results and business update moderately affect financial performance and investor sentiment.
26 Mar
RenovoRx's Phase III TIGeR-PaC trial for pancreatic cancer has surpassed 100 randomized patients and nears full enrollment completion. Nearing Phase III enrollment completion advances key trial toward data readout and potential approval, significantly impacting stock performance and prospects.
23 Mar
RenovoRx, Inc. (RNXT) closed an oversubscribed $10 million private placement priced at market, attracting strong investor demand and providing capital for clinical development and operations. Oversubscribed $10 million raise signals strong investor confidence and funds key clinical advancements for the biotech firm.
18 Mar
RenovoRx, Inc. (RNXT) announces $10 million private placement priced at-the-market to fund clinical trials and operations. $10 million funding bolsters RenovoRx's cash position for advancing cancer therapy trials and extending operational runway.
28 Feb
RenovoRx advances adoption of its RenovoCath device at U.S. cancer centers. Advancing RenovoCath adoption at cancer centers represents a major commercialization milestone that could significantly boost revenue and investor sentiment.
27 Feb
RenovoRx advances RenovoCath® adoption at U.S. cancer centers, strengthening clinical and commercial momentum. RenovoCath adoption expansion at cancer centers signals major commercial progress with potential to significantly elevate market performance.
26 Feb
RenovoRx, Inc. (RNXT) announces acceptance of its clinical data abstract for presentation at the 2026 Society of Interventional Radiology Annual Scientific Meeting. Abstract acceptance validates clinical progress and offers visibility at a major conference, moderately impacting investor sentiment and competitive positioning.